Latest News

  • Solving real-world problems with real-world data (RWD)
    How RWD and technology can help the life sciences industry re-invent clinical development
  • Nasal spray medicine for treatment-resistant depression not recommended by NICE
    A nasal spray for treatment-resistant depression has not been recommended by NICE because of uncertainties over its clinical and cost effectiveness.
  • Doubts raised about effectiveness of HPV vaccines
    A new analysis of the clinical trials of HPV vaccines to prevent cervical cancer raises doubts about the vaccines’ effectiveness. The analysis, published by the Journal of the Royal Society of Medicine, assessed 12 published Phase 2 and 3 randomised controlled efficacy trials of the HPV vaccines Cervarix and Gardasil.
  • New clinical research measures needed to ensure patient safety and advance drug development
    New campaign launches on inaugural World Patient Safety Day Maidenhead, United Kingdom, 17 September 2019 – IAOCR has launched a new campaign calling on the industry to prioritize ensuring the competence of those undertaking clinical research in-line with upcoming guideline changes. The ‘Don’t Risk Your Research’ campaign, launched on World Patient Safety Day, further supports the imminent changes to ICH E8(R1) which focuses on factors improving the ‘quality’ of clinical research specifically around the “Right First Time” approach to quality assurance.
  • Dementia charity launches mass survey to help shape future treatments
    Alzheimer’s Research UK, the UK’s leading dementia research charity, is asking people to take part in a new survey that could help shape future treatments for dementia. The online survey asks for people’s views on the aspects of daily life that are most important to them, and which they’d most like to protect if they were to develop a disease that causes dementia. The survey has launched today, Tuesday 20 August
view more


view more


  • The Promise of Epigenetics in Early Stage Drug Discovery
    Epigenetic targets are exciting to drug discovery scientists because they hold great potential across a wide spectrum of therapeutic areas. The field of epigenetics focuses on the investigation of enzymes that alter gene expression through modification of their target substrates, usually through the addition or removal of methyl or acetyl groups. High-throughput assays to identify agents capable of modifying the action of such enzyme targets has, in the past, proven to be challenging due to the relatively small molecular alterations in addition to the possibility of sequential modifications, leading to multiple end products. As such, high-throughput bioassays that allow the direct, concurrent quantification of multiple modification states are attractive. The RapidFire platform enables high-throughput mass spectrometric analysis of native molecules from in vitro reactions by performing on-line desalting in seconds, as opposed to HPLC, which requires minutes. Moreover, the RapidFire system can be connected to any mass spectrometer providing unparalleled versatility in reaction detection.
  • Integrated Quant / Qual for In-vivo Discovery Bioanalysis using Hybrid Quadrupole-Time-of-Flight Mass Spectrometry
    Ultra high performance liquid chromatography (UHPLC) coupled with orthogonal acceleration hybrid quadrupole-time-of-flight (QqTOF) mass spectrometry is an emerging technique offering new strategies for the efficient screening of new chemical entities (NCE) and related molecules at the early discovery stage within the pharmaceutical industry.
  • Drug Delivery: enabling technology for discovery and development
    The integration of pharmacodynamic and pharmacokinetic parameters in non clinical pharmacology studies is a key aspect in drug discovery for efficacy and safety assessment, in the particular for the translation from the non clinical to the clinical field. Modeling the profile of plasma exposure achieved with the intended therapeutic route often requires the use of intravenous infusion. In addition, in most cases infusion parameters (infusion rate, volume, duration and sequences) need to be customized to achieve the appropriate pattern of plasma drug exposure. When pharmacodynamic parameters are recorded by telemetry, the use of implantable pumps rather than external pumps is necessary to preserve the improvement in physiological data recording offered by telemetry.
  • Part 2: How has HR-MS technology fundamentally changed the way we study drug biotransformation and disposition?
    AB SCIEX is proud to present the 2nd installment of a Global 4-Part Live Webinar Series exploring novel and dynamic workflows for Metabolite Identification & Drug Metabolism solutions as it pertains to the 4 main stages of the drug discovery and development paradigm, Lead Discovery, Late Stage Discovery, Early Development and Late Stage Development. Part 2 of this webinar series will focus on how HRMS technology has fundamentally changed the way metabolite biotransformations are investigated in Lead Discovery.
view more


  • Securing reliability and validity in biomedical research: an essential task
    This article discusses the impact of ‘old’ and contemporary data on hypothesis generation in relation to human physiology and in the effort to optimally implement translational sciences.
  • Translational research the changing landscape of drug discovery
    In this article the author discusses how the increasing adoption of translational research is leading to novel integrated discovery nexuses that may change the landscape of drug discovery.
  • Translational medicines research
    This article discusses fundamental processes of translational research: Understanding the biological basis of human disorders; Lead generation and optimisation; Clinical testing
  • Translational CNS medicines research
    Translating neuroscience research into new medicines is challenging, largely because of the complexity of the human brain. The critical factors involved in this process are considered, along with the future prospects.
  • Decision support methods for the detection of adverse events
    Spontaneous reporting is a crucial component of post-marketing drug safety surveillance despite its significant limitations. The size and complexity of some spontaneous reporting system databases represent a challenge for drug safety professionals who traditionally have relied heavily on the scientific and clinical acumen of the prepared mind. Computer algorithms that calculate statistical measures of reporting frequency for huge numbers of drug-event combinations are increasingly used to support pharamcovigilance analysts screening large spontaneous reporting system databases.
view more

25 Hottest Articles

view more